Tag: Canagliflozin

SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk

Presented By
Dr Muthiah Vaduganathan, Brigham and Women's Hospital, USA
Conference
HFA 2024
Type
Peer-reviewed article

16 July 2024 16:42

Cardiovascular disease and diabetes: new guidelines

Presented By
Prof. Emanuele Di Angelantonio; Prof. Nikolaus Marx; Dr Katharina Schuett; Prof. Dirk Müller-Wieland; Prof. Bianca Rocca
Conference
ESC 2023
Type
Peer-reviewed article

30 October 2023 16:02

CHIEF-HF: Canagliflozin improves health status in heart failure

Presented By
Prof. John Spertus, University of Missouri-Kansas City, USA
Trial
Phase 3, CHIEF-HF
Conference
AHA 2021
Type
Peer-reviewed article

14 January 2022 14:59

2021 ESC Guidelines on Heart Failure

Presented By
Prof. Carolyn Lam, Duke-NUS Medical School, Singapore
Conference
ESC 2021
Type
Peer-reviewed article

26 October 2021 12:34

Biomarker panel predicts SGLT2 inhibitor response

Presented By
Dr Muthiah Vaduganathan, Brigham and Women´s Hospital, MA, USA
Trial
CANVAS
Conference
HFA 2021
Type
Peer-reviewed article

19 August 2021 09:33
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com